SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano (ADA) is generating intense discussion as a vocal segment of its community anticipates a "parabolic" price explosion and "third wave rally" following a perceived market correction, urging others to "buy the dip" for what they call a lifetime opportunity. However, a strong counter-narrative views ADA as a "scam" or "rugpull," pointing to long-term underperformance and questioning its leadership amid broader crypto market uncertainty.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

Invesco QQQ Trust is trending as geopolitical tensions escalate following tariff threats from the US against European allies, stemming from discussions around Greenland. The community is actively debating the market's resilience, with some anticipating a significant pullback while others expect the "buy the dip" mentality to prevail amidst concerns over global trade relations and potential economic shifts.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending amid fervent community discussion about potential credit card interest rate caps, seen as a significant tailwind for its merchant-funded, zero-interest payment model. This perception is bolstered by strong holiday spending reports indicating surging BNPL adoption and Klarna's strategic push into stablecoins. Investors are actively debating its undervaluation and long-term growth potential in a shifting credit landscape, despite recent market volatility.

Secret is the native coin of the Secret Network, a decentralized network for private / secure computation. Nodes on the network (known as secret nodes) can perform generalizable computations over encrypted data, which allows smart contracts (known as secret contracts) to use private and sensitive data as inputs. Our focus is on computational privacy, not just transactional privacy. Developers can build decentralized, privacy-preserving "Secret Apps" on the network. The privacy functionality of the Secret Network is critical for many fields, including decentralized finance, Web3, machine learning, access control, and many more.  The Secret Network is supported by many independent development teams and entities, including Enigma, Secret Foundation, Secretnodes.org, Chain of Secrets, and more

Secret 

Secret Network (SCRT) is gaining attention for its advancements in confidential AI and expanded integrations, bringing privacy-preserving computing to multiple blockchain ecosystems like Arbitrum and ZKsync Era. The community is buzzing about SCRT's long-term potential as a critical Web3 infrastructure, driven by its unique blend of data privacy and AI capabilities, alongside appealing staking rewards.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing immense momentum driven by Saudi FDA approval for its ANKTIVA therapy in lung and bladder cancer, alongside significant revenue growth. The community is eagerly anticipating a substantial short squeeze, propelled by high insider ownership and widespread conviction in the company's groundbreaking immunotherapy platform and its potential to revolutionize cancer treatment.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is trending following its V4 testnet launch, strategic expansion plans including a consumer savings app and EU regulatory license, and a recent SEC probe conclusion with no enforcement action. The community is actively discussing AAVE's "undervalued" status and superior position compared to rivals, driven by its robust Real World Asset integration and a proposed token buyback program.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending due to multiple recent analyst upgrades, notably an "Outperform" rating and a $320 price target from Evercore ISI, driven by expectations of robust AI-fueled growth and enhanced ad monetization. The community is keenly discussing its potential as a high-value data provider for AI training, contrasting this bullish outlook with recent market volatility and concerns stemming from some negative ad-performance feedback and insider selling ahead of upcoming earnings.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is generating significant market conversation following the launch of its new InDensity battery storage platform, a high-density, non-flammable zinc-based solution critical for AI-driven data centers and urban grids. The community eagerly anticipates a major breakout, with many pointing to bullish technical patterns and the escalating demand for domestic energy storage, while some observers remain cautious given recent price volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as former President Trump's proposal to acquire Greenland, alongside related tariff threats against European nations, dominates conversation. This geopolitical move has sparked intense community debate, with supporters viewing it as strategic for national security and critics warning of global alienation and market instability. Investor sentiment remains highly polarized, reflecting concerns over potential economic repercussions.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble Inc. is trending after launching its crypto wallet with Tether, enabling direct creator payments, and advancing its Northern Data acquisition, poised to substantially boost its AI and cloud infrastructure. The community anticipates a notable short squeeze, citing high short interest and significant insider ownership, while also highlighting Tether's considerable financial commitments and Rumble's strategic growth into a decentralized creator economy and cloud provider.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>With a broad, strategic suite of programs, Goldman Sachs views BioNTech as “being at the nexus of significant developments occurring in the oncology field.”</li><li>BioNTech is now looking to strengthen its oncology portfolio as it pivots away from its Covid-19 vaccine Comirnaty developed with Pfizer.&nbsp;</li><li>BioNTech’s oncology pipeline comprises late-stage candidates spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies.</li></ul>Shares of BioNTech SE (BNTX) rose 3% on Friday after Goldman Sachs upgraded the stock to ‘Buy’ from ‘Neutral’.Goldman also raised the price target on the stock to $142, up from $115, according to TheFly. The new price target represents a potential upside of about 34% from the stock’s closing price on Thursday. &nbsp;<h2 class="st-heading-2">Goldman’s Rationale</h2>With a broad, strategic suite of programs, Goldman Sachs views BioNTech as “being at the nexus of significant developments occurring in the oncology field” and uniquely positioned to develop novel combination approaches to transform cancer care.Data unlocks in 2026 could position the company with “a leading foothold in an emerging wave of new product cycles,” the analyst added.<h2 class="st-heading-2">Pipeline</h2>BioNTech is now looking to strengthen its oncology portfolio as it pivots away from its Covid-19 vaccine Comirnaty developed with Pfizer.BionTech’s oncology pipeline comprises late-stage candidates spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. It is also developing several combination approaches.In 2026, the company expects seven late-stage data readouts, and also looks forward to applying to the U.S. Food and Drug Administration (FDA) for approval of its drug T-Pam in endometrial cancer. BioNTech hopes to become a multi-product oncology company by 2030.The company, however, does not currently anticipate the recognition of revenues from the sale of any oncology products in 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around BNTX stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user, however, highlighted concerns with the company’s recent acquisition of CureVac. BioNTech closed the acquisition of CureVac in December after<a href="https://stocktwits.com/news-articles/markets/equity/biontech-to-acquire-curevac-in-all-stock-deal-valued-at-1.25-billion/chlXz8nRb6u"> announcing </a>the all-stock deal in June to support its oncology strategy.<stembedurl>https://www.stocktwits.com/taxplanr/message/642106083</stembedurl><a href="https://stocktwits.com/symbol/BNTX">BNTX stock</a> has fallen 3% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/genmab-reports-mixed-results-from-late-stage-trial-of-lymphoma-drug/cmUmGfeR4Bt">Genmab Stock Drops On Mixed Results From Late-Stage Trial Of Lymphoma Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioNTech logo is displayed on a smartphone screen. (Photo illustration by Cheng Xin/Getty Images)

BNTX Shares Rise On Goldman Sachs Upgrade, Optimism For Cancer Portfolio

Goldman raised the price target on BioNTech SE to $142, up from $115.

Equity

SG Americas Securities LLC Sells 69,726 Shares of BioNTech SE Sponsored ADR $BNTX

SG Americas Securities LLC lessened its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 77.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The...

BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock?

BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset mounting generic pressure

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Recommendation of "Moderate Buy" from Analysts

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) has received a consensus rating of "Moderate Buy" from the fifteen ratings firms that are presently covering the firm, Marketbeat.com...

<ul class="summary-bullets"><li>The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial guidance, the company said.</li><li>Genmab assumed sole responsibility for the continued development of Acasunlimab in August 2024 after BioNTech opted out.</li><li>Acasunlimab is an investigational bispecific antibody designed to elicit an antitumor response.</li></ul>Genmab A/S (GMAB) on Monday said that it will discontinue further clinical development of Acasunlimab as part of its efforts to focus on the most value-creating areas.The clinical profile observed of Acasunlimab has been encouraging to date, but the company has decided to concentrate on cancer therapies Epkinly, Petosemtamab and Rina‑S, which are in late-stage development, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.genmab.com/news-releases/news-release-details/genmab-portfolio-prioritization-update">said.</a> &nbsp;“Although the data have been encouraging, the compelling opportunities we see in our late‑stage pipeline led us to focus our investments where we believe we can deliver the greatest benefit for patients and shareholders. We are highly energized by the momentum of EPKINLY, petosemtamab and Rina‑S, and we remain committed to executing these programs with speed and rigor,” said Genmab CEO Jan van de Winkel.NASDAQ-listed shares of the company fell 2% at the time of writing.<h2 class="st-heading-2">Collaboration With BioNTech</h2>The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial guidance, the company said.The discontinued drug was developed by Copenhagen based Genmab with Germany based BioNTech. Genmab assumed sole responsibility for the continued development of Acasunlimab in August 2024 after BioNTech opted out citing reasons relating to its portfolio strategy.Acasunlimab is an investigational bispecific antibody designed to elicit an antitumor response. It was being studied in multiple trials including one in patients with non-small cell lung cancer (NSCLC).<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around GMAB stayed within the ‘bullish’ territory accompanied by ‘low’ message volume while sentiment around <a href="https://stocktwits.com/symbol/BNTX">BNTX</a> stayed within ‘neutral’ territory with ‘normal’ levels of retail chatter.<a href="https://stocktwits.com/symbol/GMAB">GMAB stock</a> has gained 57% this year and by about 58% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-supplier-reportedly-slashes-contract-in-part-due-to-lower-than-expected-cybertruck-demand/cL7dT7ARExx">Tesla Supplier Reportedly Slashes Contract In Part Due To Lower-Than-Expected Cybertruck Demand</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

This Image Is A Part Of A Series On Pulmonary Pathologies. (Photo By BSIP/UIG Via Getty Images)

Genmab Stock Slips After Discontinuing Further Development Of Cancer Drug Developed With BioNTech

The company has decided to concentrate on cancer therapies Epkinly, Petosemtamab and Rina‑S, which are in late-stage development. 

BioNTech SE Sponsored ADR $BNTX Shares Sold by TB Alternative Assets Ltd.

TB Alternative Assets Ltd. lessened its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 92.7% in the 3rd quarter, according to the company in its most recent 13F filing...

Vontobel Holding Ltd. Purchases 10,924 Shares of BioNTech SE Sponsored ADR $BNTX

Vontobel Holding Ltd. boosted its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 17.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and...

Hudson Bay Capital Management LP Sells 15,000 Shares of BioNTech SE Sponsored ADR $BNTX

Hudson Bay Capital Management LP cut its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 9.1% in the second quarter, according to the company in its most recent filing with the...

FY2025 EPS Estimates for BioNTech Decreased by HC Wainwright

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) - Analysts at HC Wainwright reduced their FY2025 EPS estimates for shares of BioNTech in a research note issued to investors on Wednesday...

Gilder Gagnon Howe & Co. LLC Has $71.08 Million Position in BioNTech SE Sponsored ADR $BNTX

Gilder Gagnon Howe & Co. LLC grew its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 2.8% in the 2nd quarter, according to the company in its most recent disclosure with the...

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Current Price	$108.77
Prev Close	$106.07
Open	$109.24
Dividend Yield	0.00%
50-Day Moving Average	$99.06
Beta	0.82
Avg. Volume	1.44M
PE Ratio	-41.43

52-Week High	$126.77
52-Week Low	$81.20
Market Capitalization	$26.21B
EPS (Annual)	-$2.99
Price to Book	1.21
Revenue Per Employee	$439,432.88
Enterprise Value/EBITDA	N/A

BNTX
BioNTech SE - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BNTX News

BNTXBioNTech SE - ADR